Therapeutic compounds
US-2017298040-A1 · Oct 19, 2017 · US
Tricyclic urea compounds as JAK2 V617F inhibitors
US12084430B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12084430-B2 |
| Application number | US-202318122323-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 16, 2023 |
| Priority date | Mar 17, 2022 |
| Publication date | Sep 10, 2024 |
| Grant date | Sep 10, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound, which is methyl ((1R,3R)-3-(7-(3-fluoro-1-(methyl-d 3 )-1H-pyrazol-4-yl)-8-(4-fluorophenyl)-3-(methyl-d 3 )-2-oxo-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(2)-yl)cyclopentyl)carbamate, or a pharmaceutically acceptable salt thereof. 2. A compound, which is methyl ((1R,3R)-3-(8-(1,1-dimethyl-1,3-dihydroisobenzofuran-5-yl)-7-(3-fluoro-1-(methyl-d3)-1H-pyrazol-4-yl)-3-(methyl-d3)-2-oxo-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(2H)-yl)cyclopentyl)carbamate, or a pharmaceutically acceptable salt thereof. 3. A pharmaceutical composition, comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 4. A pharmaceutical composition, comprising the compound of claim 2 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 5. A compound, which is methyl ((1R,3R)-3-(8-(4-fluorophenyl)-7-(3-methoxy-1-methyl-1H-pyrazol-4-yl)-3-methyl-2-oxo-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(2H)-yl)cyclopentyl)carbamate, or a pharmaceutically acceptable salt thereof. 6. A pharmaceutical composition, comprising the compound of claim 5 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 7. The compound of claim 1 , which is methyl ((1R,3R)-3-(7-(3-fluoro-1-(methyl-d 3 )-1H-pyrazol-4-yl)-8-(4-fluorophenyl)-3-(methyl-d 3 )-2-oxo-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(2H)-yl)cyclopentyl)carbamate. 8. A pharmaceutical composition, comprising the compound of claim 7 , and a pharmaceutically acceptable carrier. 9. The compound of claim 2 , which is methyl ((1R,3R)-3-(8-(1,1-dimethyl-1,3-dihydroisobenzofuran-5-yl)-7-(3-fluoro-1-(methyl-d3)-1H-pyrazol-4-yl)-3-(methyl-d3)-2-oxo-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(2H)-yl)cyclopentyl)carbamate. 10. A pharmaceutical composition, comprising the compound of claim 9 , and a pharmaceutically acceptable carrier. 11. The compound of claim 5 , which is methyl ((1R,3R)-3-(8-(4-fluorophenyl)-7-(3-methoxy-1-methyl-1H-pyrazol-4-yl)-3-methyl-2-oxo-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(2H)-yl)cyclopentyl)carbamate. 12. A pharmaceutical composition, comprising the compound of claim 11 , and a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
specific for leukemia · CPC title
Antineoplastic agents · CPC title
the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline · CPC title
- C07D471/14Primary
Ortho-condensed systems · CPC title
- C07D401/14Primary
containing three or more hetero rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12084430B2 cover?
- The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
- Who is the assignee on this patent?
- Incyte Corp
- What technology area does this patent fall under?
- Primary CPC classification C07D471/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).